Anzeige
Mehr »
Dienstag, 14.07.2026 - Börsentäglich über 12.000 News
Time to Buy! Diese drei Kräfte treiben die Tiefsee-Exploration massiv an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
171 Leser
Artikel bewerten:
(1)

National Association for Biomedical Research: NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act

The U.S. Fish and Wildlife Service determined that PETA's petition1 to list LTM monkeys under the ESA does not present substantial scientific information warranting further review. This is the second time USFWS has rejected a petition from PETA to list this nonhuman primate species in the last three years2.

"The National Association for Biomedical Research commends USFWS for conducting a thorough, science-based review of the petition submitted by activist groups and for its determination that LTM monkeys do not warrant listing under the ESA," said Matthew R. Bailey, president, National Association for Biomedical Research (NABR).

"It is clear from the record that activist groups like PETA have attempted to weaponize the ESA and other environmental processes to block or hinder medical research in the United States and around the world. Doing so not only jeopardizes human health and safety, but it undermines the value of these environmental processes when they are used as tools to further political agendas," added Mr. Bailey.

"NABR will continue to engage in these processes to protect medical research in the U.S. and around the world to ensure decisions regarding species protection are based on the best available scientific and commercial data."

LTM monkeys are used extensively throughout the world in biomedical research given their close approximation to human beings. The importation and use of this nonhuman primate species in biomedical research is strictly regulated by international bodies and U.S. federal agencies.

Medical research using LTM monkeys has been crucial for advances in regenerative medicine3, immunology4, cancer5, vaccine development6, and pharmacology7. The National Institutes of Health (NIH) recently published a review confirming the importance of LTM monkeys in conducting biomedical research8.

"Due to their physiological and biological similarities with humans, LTM monkeys are a crucial resource for pre-clinical biomedical research. They contribute to the development of therapies before the human clinical trial stage of development," said Mr. Bailey. "LTM monkeys have been instrumental in the development, and in safety and efficacy assessment, of many of today's medicines and treatments. They continue to be invaluable for biomedical advancements."

About the National Association for Biomedical Research
Founded in 1979, the National Association for Biomedical Research (NABR) is the only 501(c)(6) nonprofit association dedicated to sound public policy for the humane use of animals in biomedical research, education, and testing. Members include more than 280 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and animal health. Learn more about us at www.nabr.org.


1 https://www.peta.org/media/news-releases/peta-primate-experts-file-legal-petitions-to-new-administration-to-protect-monkeys-not-profits/
2 https://www.nabr.org/about-nabr/news/fish-wildlife-service-long-tailed-macaques-esa
3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848615/#:~:text=Non%2Dhuman%20primates%20play%20a,organs%20affected%20by%20degenerative%20diseases. regenerative medicine
4 https://www.nature.com/articles/s41577-018-0005-7. immunology
5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808758/#:~:text=Furthermore%2C%20NHP%20naturally%20develop%20cancers,and%20patients%20with%20human%20cancer. cancer therapies
6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402317/. vaccine development
7 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886327/. pharmacology
8 https://orip.nih.gov/about-orip/research-highlights/nonhuman-primate-evaluation-and-analysis-final-report

Eva Maciejewski
emaciejewski@nabr.org
(202) 967-8305

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/nabr-the-us-fish-and-wildlife-service-for-the-second-time-rejects-activists-petition-to-list-long-tailed-macaque-monkeys-under-the-endangered-species-act-302825307.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.